SLP Simulations Plus

Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who Code

(Nasdaq: SLP) today announced its final donation in celebration of 25 years in business. During this 25th anniversary year, which commenced in July 2021, teams of long-tenured Simulations Plus employees researched various organizations and selected recipients aligned with the Company’s vision, mission, and values. This fourth and final $25,000 donation was made to , an international organization headquartered in New York, NY, with more than 8,500 programs worldwide dedicated to closing the gender gap in technology. The donation was made on August 16, 2022.

“We are excited to close out our 25th anniversary celebration with this $25,000 donation to Girls Who Code,” said , Human Resources Director for Simulations Plus. “Their main mission, to close the gender gap in STEM, is one that closely aligns with our continued commitment to diversity and inclusion. As an organization where women make up 52% percent of our scientific staff, it’s important that we continue to encourage and support girls from a young age to grow in these fields, and we look forward to more opportunities to partner with Girls Who Code in the future.”

“At Girls Who Code, we know that to change what a programmer looks like and does, we must continue to make STEM accessible to all our students, especially those from historically underrepresented groups and low-income communities,” said Dr. Tarika Barrett, CEO of Girls Who Code. “We are grateful to Simulations Plus for supporting our mission to close the gender gap in tech and providing our students with resources to thrive in their classrooms, communities, and beyond.”

About Girls Who Code

Girls Who Code is an international nonprofit organization working to close the gender gap in technology, and leading the movement to inspire, educate, and equip students who identify as girls or nonbinary with the computing skills needed to pursue 21st century opportunities. Since launching in 2012, Girls Who Code has reached 500,000 students through our in-person and virtual programming, and 115,000 of our alumni are college-aged or early career professionals. Girls Who Code has sparked culture change through marketing campaigns and advocacy efforts, generating 14 billion engagements globally. In 2019, the organization was named the #1 Most Innovative Non-Profit on Fast Company’s Most Innovative Companies list, and in 2022 was named one of The NonProfit Times’ Best Nonprofits to Work For.

About Simulations Plus

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at . Follow us on | | .

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

EN
03/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Simulations Plus

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

 PRESS RELEASE

Simulations Plus and Enabling Technologies Consortium Announce Strateg...

RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform. The collaboration focuses on enhancing the predictive capabiliti...

 PRESS RELEASE

Simulations Plus Supported Development of Every FDA-Approved Drug in 2...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the . “For more than 25 years, our clients have entrusted us to provide the mission-critical software and services needed to develop therapies that are changing the landscape of healthcare,” said , Chief Executive Officer at Simulations Plu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch